We are proud to announce the return of their 3rd annual
Immunogenicity event to London in 2016! Biologics is a leading growth area in the Pharmaceutical industry with growth rates 2 -3 times as fast as chemical entities. The challenges for the biopharmaceutical market are different to those from traditional chemical entities.
Immunogenicity continues to be a major concern for the field of science, due to its impact on safety and efficacy. The challenging task of
immunogenicity assessment of a biopharmaceutical drug's immunogenic potential remains at the forefront of challenges.
Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with
immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!
Benefits of Attending
- Gain insight into how tackle the challenges involved with the assessment of early risks in immunogenicity
- Hear key feedback from regulatory authorities on how to increase your speed to market
- Participate in insightful discussions on; nanobodies, ADCs, biosimilars and many more!
Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday 15th June 2016
A: Approaches to standardising assays for measuring drug levels and anti drug antibodies to biotherapeutics in clinical practiceWorkshop Leaders: Hishani Kirby, Founder and Director, Hishani Kirby Associates Ltd
Daniel Sikkema, Executive Director, Head of Immunogenicity and Clinical Immunology, GlaxoSmithKline
08.30 - 12.30
B: Unwanted immunogenicity from bench to bedside Workshop Leaders: Arno Kromminga, CEO/CSO, IPM Biotech
Sofie Pattijn, Chief Technology Offi cer, ImmunXperts
13.30 - 17.30
Speakers
- Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
- Andreas Herrmann, CEO, Baliopharm AG
- Annie Groot, CEO/CSO, EpiVax, Inc.
- Chloe Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University Of Brussels
- Daniel Sikkema, Head BioPharma Clinical Immunology, GSK
- Jeremy Derrick, Professor, University Of Manchester
- Jeremy Fry, Director of Sales, ProImmune Ltd.
- Jochem Gokemeijer, Associate Director, Bristol Myers Squibb
- Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals
- Machteld Tiemessen, Senior Scientist, Janssen
- Mantas Malisauskas, Manager R&D, Baxalta
- Mark Fogg, Immunology Group Leader, Abzena
- Meenu Wadhwa, Head, Cytokines & Growth Factors & Biotherapeutics, NIBSC, MHRA
- Sue Charlton, Scientific Lead, Vaccine Research Group, , Public Health England
- Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
- Timothy Hickling, Immunogenicity Sciences Discipline Lead, Pfizer Pharmaceuticals
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Who should attend
You should attend this event if you are a working within the fiel d of immun with responsibilities in the following areas:
- Immunologists
- Chief Scientific Officer
- Head of Bioanalytical Services
- Director of Immunology
- Professor of Immunology/Immunogenicity
- Professor of Experimental Pathology
- Senior Expert Immunogenicity
- Head of Advanced Protein Technologies
- Global head of Exploratory Statistics
- Scientific Investigator, Clinical Immunology
- Development DMPK Project Leader
Venue
Holiday Inn Kensington Forum97 Cromwell Road
London, United Kingdom
